

|  |  |  |  |                                       |  |                               |  |
|--|--|--|--|---------------------------------------|--|-------------------------------|--|
| Substitute Form PTO-1449<br>(Modified)   |  | U.S. Department of Commerce<br>Patent and Trademark Office |  | Attorney's Docket No.<br>15665-007US1 |  | Application No.<br>10/563,389 |  |
| <b>Information Disclosure Statement<br/>by Applicant</b><br>(Use several sheets if necessary)<br><br>(37 CFR §1.98(b)) |  |  |  | Applicant<br>Claesson Welsh et al.    |  |                               |  |
|  |  |  |  | Filing Date<br>February 15, 2007      |  | Group Art Unit<br>1614        |  |

| <b>U.S. Patent Documents</b> |           |                 |                  |          |       |          |                            |
|------------------------------|-----------|-----------------|------------------|----------|-------|----------|----------------------------|
| Examiner Initial             | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|                              |           |                 |                  |          |       |          |                            |

| <b>Foreign Patent Documents or Published Foreign Patent Applications</b> |           |                 |                  |                          |       |          |                    |
|--|-----------|-----------------|------------------|--------------------------|-------|----------|--------------------|
| Examiner Initial   | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation Yes No |
|  |           |                 |                  |                          |       |          |                    |

| <b>Other Documents (include Author, Title, Date, and Place of Publication)</b> |           |  |
|--|-----------|--|
| Examiner Initial   | Desig. ID | Document   |
|  | 1.        | Borza and Morgan, "Histidine-Proline-rich Glycoprotein as a Plasma pH Sensor," <u>J. Biol. Chem.</u> , 1998, 273(10):5493-5499   |
|  | 2.        | Borza and Morgan, "Acceleration of Plasminogen Activation by Tissue Plasminogen Activator on Surface-bound Histidine-proline-rich Glycoprotein," <u>J. Biol. Chem.</u> , 1997, 272(8):5718-5726          |
|  | 3.        | Brown and Parish, "Histidine-Rich Glycoprotein and Platelet Factor 4 Mask Heparan Sulfate Proteoglycans Recognized by Acidic and Basic Fibroblast Growth Factor," <u>Biochem.</u> , 1994, 33:13918-13927 |
|  | 4.        | Carmeliet and Jain, "Angiogenesis in cancer and other diseases," <u>Nature</u> , 2000, 407:249-257   |
|  | 5.        | Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <u>Nature Med.</u> , 1995, 1(1):27-31   |
|  | 6.        | Gorgani et al., "Histidine-Rich Glycoprotein Binds to Human IgG and C1q and Inhibits the Formation of Insoluble Immune Complexes," <u>Biochem.</u> , 1997, 36:6653-6662                                  |
|  | 7.        | Gorgani et al., "Histidine-Rich Glycoprotein Binds to DNA and Fc $\gamma$ RI and Potentiates the Ingestion of Apoptotic Cells by Macrophages," <u>J. Immunol.</u> , 2002, 169:4745-4751                  |
|  | 8.        | Gura, "Cancer Models: Systems for Identifying New Drugs Are Often Faulty," <u>Science</u> , 1997, 278:1041-1042  |
|  | 9.        | Hawighorst et al., "Activation of the Tie2 Receptor by Angiopoietin-1 Enhances Tumor Vessel Maturation and Impairs Squamous Cell Carcinoma Growth," <u>Am. J. Pathol.</u> , 2002, 160(4):1381-1392       |
|  | 10.       | Kerbel, "Tumor angiogenesis: past, present and the near future," <u>Carcinogenesis</u> , 2000, 21(3):505-515   |
|  | 11.       | Koide et al., "The heparin-binding site(s) of histidine-rich glycoprotein as suggested by sequence homology with antithrombin III," <u>FEBS</u> , 1986, 194(2):242-244                                   |
|  | 12.       | Kluszynski et al., "Zinc as a Cofactor for Heparin Neutralization by Histidine-rich Glycoprotein," <u>J. Biol. Chem.</u> , 1997, 272(21):13541-13547   |
|  | 13.       | Lamb-Wharton and Morgan, "Induction of T-Lymphocyte Adhesion by Histidine-Proline-Rich Glycoprotein and Concanavalin A," <u>Cell. Immunol.</u> , 1993, 152:544-555                                       |
|  | 14.       | Lijnen et al., "Heparin Binding Properties of Human Histidine-rich Glycoprotein. Mechanism and Role in the Neutralization of Heparin in Plasma," <u>J. Biol. Chem.</u> , 1983, 258(6):3803-3808          |
|  | 15.       | Olsen et al., "Histidine-rich glycoprotein binding to T-cell lines and its effect on T-cell substratum adhesion is strongly potentiated by zinc," <u>Immunology</u> , 1996, 88:198-206                   |
|  | 16.       | Peterson et al., "Histidine-rich Glycoprotein Modulation of the Anticoagulant Activity of Heparin," <u>J. Biol. Chem.</u> , 1987, 262(16):7567-7574  |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

|  |  |                                       |                               |
|--|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449<br>(Modified)   | U.S. Department of Commerce<br>Patent and Trademark Office | Attorney's Docket No.<br>15665-007US1 | Application No.<br>10/563,389 |
| <b>Information Disclosure Statement<br/>by Applicant</b><br>(Use several sheets if necessary)<br><br>(37 CFR §1.98(b)) |  | Applicant<br>Claesson Welsh et al.    |                               |
|  |  | Filing Date<br>February 15, 2007      | Group Art Unit<br>1614        |

| <b>Other Documents (include Author, Title, Date, and Place of Publication)</b> |           |  |
|--|-----------|--|
| Examiner Initial   | Desig. ID | Document   |
|  | 17.       | Simon et al., "Peptoids: A modular approach to drug discovery," <u>Proc. Natl. Acad. Sci. USA</u> , 1992, 89:9367-9371   |
|  | 18.       | Zhang et al., "Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5," <u>FASEB J.</u> , 2000, 14:2589-2600 |
|  | 19.       | Wassberg et al., "Inhibition of Angiogenesis Induces Chromaffin Differentiation and Apoptosis in Neuroblastoma," <u>Am. J. Pathol.</u> , 1999, 154(2):395-403                                  |

|  |                 |
|--|-----------------|
| Examiner Signature   | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |